SCHEMBL5044122

SCHEMBL5044122

Nc1cc(C=Cc2ccc3c(C(=O)O)cccc3c2)ncn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.45
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
CYSLTR1 Q9Y271 3/20 0.40
CYSLTR2 Q9NS75 2/20 0.40
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
KDR P35968 4/20 0.39
FLT1 P17948 3/20 0.39
FLT4 P35916 2/20 0.39
TEK Q02763 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PKM P14618 1/20 0.37
APP P05067 4/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044118 1.00 PTPN1 (0.45) PTPN1KDM4EALDH1A1MEN1HPGD
SCHEMBL5049717 1.00 PTPN1 (0.45) PTPN1KDM4EALDH1A1MEN1HPGD
SCHEMBL2434146 0.78 KDR (0.68) KDRFLT1FLT4TEK
SCHEMBL2435774 0.78 KDR (0.68) KDRFLT1FLT4TEK
SCHEMBL2435108 0.75 PTPN1 (0.49) PTPN1ALDH1A1MEN1KMT2ANR4A1
SCHEMBL2436216 0.75 KDR (0.63) PTPN1KDRFLT1FLT4TEK
SCHEMBL2709142 0.74 PTPN1 (0.45) PTPN1MEN1KMT2ANR4A1NR4A2
SCHEMBL3583506 0.72 TBXAS1 (0.47) PTPN1ALDH1A1NR4A1NR4A2NR4A3
SCHEMBL7196013 0.72 PTPN1 (0.62) PTPN1KDM4EALDH1A1MEN1HPGD
SCHEMBL2709771 0.71 PTPN1 (0.48) PTPN1KDM4EALDH1A1NR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 US disclosed
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors NOVARTIS AG (CH) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 PTPN1 1642/4885KDM4E 1247/4885ALDH1A1 2819/4885
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors MAP3K20, MAP3K1, MAP3K19 PTPN1 1745/4885KDM4E 1373/4885ALDH1A1 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.